Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25

Viking Therapeutics, Inc.

2025-Q1 EPS reported -$0.41

Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.
Cash, cash equivalents & short-term investments totaled $852M at March 31, 2025, down from $903M at Dec 31, 2024.
Phase 3 trials for subcutaneous VK2735 in obesity expected to begin in 2Q25; Phase 2 VENTURE-Oral Dosing trial fully enrolled, data expected 2H25.
Signed broad manufacturing agreement with CordenPharma for VK2735 API and fill/finish capacity; prepayments from 2025-2028 credited against future orders.
Dual amylin/calcitonin receptor agonist (DACRA) program IND planned for 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.